Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer (Q89036516)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 June 2018

Language	Label	Description	Also known as
English	Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer	scientific article published on 07 June 2018

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

J Pérez Fidalgo

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

author name string

Jordi Rodon

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Ian E Krop

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Howard Burris

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Angel Guerrero-Zotano

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Carolyn D Britten

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Carlos Becerra

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Jan Schellens

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Donald A Richards

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Martin Schuler

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Maysa Abu-Khalaf

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Faye M Johnson

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Malcolm Ranson

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Jeff Edenfield

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Antonio P Silva

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Wolfgang Hackl

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Cornelia Quadt

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

David Demanse

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Vincent Duval

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Jose Baselga

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

publication date

7 June 2018

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

82

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

285-298

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Cancer phase I clinical trials: efficient dose escalation with overdose control

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Critical aspects of the Bayesian approach to phase I cancer trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of Akt activity by chemotherapy confers acquired resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the phosphoinositide 3-kinase pathway in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NVP-BEZ235 as a new therapeutic option for sarcomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2 breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC

1 reference

https://pubmed.ncbi.nlm.nih.gov/29882016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-018-3610-Z

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29882016 AND SRC:MED&resulttype=core&format=json

30 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q89036516&oldid=1703981872"